Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Recruiting now · Phase 2
Conditions studied: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
In brief
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental combinations * How much study drug and fianlimab is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations
Key facts
- Study ID
- NCT06787612
- Run by
- Regeneron Pharmaceuticals
- People needed
- 220
- Starts
- 2025-05-28
- Expected to finish
- 2028-10-30
- Last updated by the study team
- 2026-07-09
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- UC San Diego Health — La Jolla, California, United States (enrolling)
- Cedars Sinai Medical Center — Los Angeles, California, United States (enrolling)
- Mayo Clinic Jacksonville — Jacksonville, Florida, United States (enrolling)
- University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida, United States (enrolling)
- Advent Health Cancer Institute — Orlando, Florida, United States (enrolling)
- Tampa General Hospital Cancer Institute — Tampa, Florida, United States (enrolling)
- University of Chicago — Chicago, Illinois, United States (enrolling)
- The University of Kansas Cancer Center — Westwood, Kansas, United States (enrolling)
- Norton Cancer Institute, St. Matthews Clinic — Louisville, Kentucky, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- Karmanos Cancer Institute — Detroit, Michigan, United States (enrolling)
- The Ohio State University Comprehensive Cancer Center — Hilliard, Ohio, United States (enrolling)
- Providence Cancer Institute — Portland, Oregon, United States (enrolling)
- University of Pittsburgh Medical Center, Magee-Womens Hospital — Pittsburgh, Pennsylvania, United States (enrolling)
- West Penn Hospital of Allegheny Health Network — Pittsburgh, Pennsylvania, United States (enrolling)
- Avera Cancer Institute Sioux Falls — Sioux Falls, South Dakota, United States (enrolling)
- UT Southwestern Medical Center — Dallas, Texas, United States (enrolling)
- Swedish Cancer Institute — Seattle, Washington, United States (enrolling)
- University of Wisconsin — Madison, Wisconsin, United States (enrolling)
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States (enrolling)
- CancerCare Manitoba — Winnipeg, Manitoba, Canada (enrolling)
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada (enrolling)
- Centre de Santé et de Services Sociaux de la Montérégie-Centre — Greenfield Park, Quebec, Canada (enrolling)
- Research Institute - McGill University Health Centre — Montreal, Quebec, Canada (enrolling)
- The University of Alabama at Birmingham — Birmingham, Alabama, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.